BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 26613644)

  • 1. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of cell-free circulating BRAF
    Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
    Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
    Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
    Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
    Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating BRAF mutations in eruptive melanocytic naevi.
    Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
    Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massively parallel sequencing analysis of benign melanocytic naevi.
    Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
    Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
    Tan JM; Tom LN; Soyer HP; Stark MS
    Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF kinase gene V599E mutation in growing melanocytic lesions.
    Loewe R; Kittler H; Fischer G; Faé I; Wolff K; Petzelbauer P
    J Invest Dermatol; 2004 Oct; 123(4):733-6. PubMed ID: 15373778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
    Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
    Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High BRAF mutation frequency does not characterize all melanocytic tumor types.
    Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
    Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
    Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
    Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.